| First Author | Wang YL | Year | 2022 |
| Journal | J Mol Cell Cardiol | Volume | 167 |
| Pages | 40-51 | PubMed ID | 35314145 |
| Mgi Jnum | J:336208 | Mgi Id | MGI:7261094 |
| Doi | 10.1016/j.yjmcc.2022.03.003 | Citation | Wang YL, et al. (2022) Osteoblast MR deficiency protects against adverse ventricular remodeling after myocardial infarction. J Mol Cell Cardiol 167:40-51 |
| abstractText | RATIONALE: Mineralocorticoid receptor (MR) antagonists have been clinically used to treat heart failure. However, the underlying cellular and molecular mechanisms remain incompletely understood. METHODS AND RESULTS: Using osteoblast MR knockout (MR(obko)) mouse in combination with myocardial infarction (MI) model, we demonstrated that MR deficiency in osteoblasts significantly improved cardiac function, promoted myocardial healing, as well as attenuated cardiac hypertrophy, fibrosis and inflammatory response after MI. Gene expression profiling using RNA sequencing revealed suppressed expression of osteocalcin (OCN) in calvaria from MR(obko) mice compared to littermate control (MR(fl/fl)) mice with or without MI. Plasma levels of undercarboxylated OCN (ucOCN) were also markedly decreased in MR(obko) mice compared to MR(fl/fl) mice. Administration of ucOCN abolished the protective effects of osteoblast MR deficiency on infarcted hearts. Mechanistically, ucOCN treatment promoted proliferation and inflammatory cytokine secretion in macrophages. Spironolactone, an MR antagonist, significantly inhibited the expression and secretion of OCN in post-MI mice. More importantly, spironolactone decreased plasma levels of ucOCN and inflammatory cytokines in heart failure patients. CONCLUSIONS: MR deficiency in osteoblasts alleviates pathological ventricular remodeling after MI, likely through its regulation on OCN. Spironolactone may work through osteoblast MR/OCN axis to exert its therapeutic effects on pathological ventricular remodeling and heart failure in mice and human patients. |
